Shares of Gland Pharma fell on Indian exchanges June 16, 2026, after the central government announced a policy requiring prescriptions for all liquid syrup medicines before dispensing, a measure that affects a meaningful share of the over-the-counter consumer healthcare segment.
Gland Pharma derives revenue from injectable and liquid formulation products, some of which had previously been accessible in pharmacy settings without a physician’s prescription. The new mandate adds a step in the purchase chain that analysts said could reduce impulse buying and pressure volumes across several product categories.
The broader pharmaceutical sector absorbed the news unevenly, with companies carrying larger exposures to cough-and-cold syrups and liquid vitamin formulations seeing sharper intraday declines. Industry associations indicated they would engage with health ministry officials on implementation timelines and product-specific scope.
Consumer health advocates expressed support for the regulation as a safeguard against formulation misuse. Analysts said the near-term revenue effect on Gland Pharma would depend on which specific products fall under the new prescription requirement and how quickly enforcement is standardized across pharmacy networks.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://trendlyne.com/markets-today/